Mekinist (Trametinib)
MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-na ve patients with unresectable or metastatic melanoma with BRAF V600E or V600K…
Medications Updated During January 2022, From Newest to Oldest, Page 14
Rifampin
In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the…
Tafinlar (Dabrafenib)
TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved…
Naproxen Delayed Release (Naproxen)
Carefully consider the potential benefits and risks of Naproxen delayed-release tablets and other treatment options before deciding to use naproxen delayed-release tablets. Use the lowest…
TECENTRIQ (Atezolizumab)
TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: Urothelial Carcinoma for the treatment of adult patients with locally advanced or metastatic urothelial…